Eli Lilly: Mounjaro And Zepbound Keep The Growth Story Alive
SeekingAlpha · 29 de oct de 2026
Eli Lilly and Company remains a Buy, as its Q3 results show strong revenue growth and rising Mounjaro and Zepbound sales. Click for a detailed LLY update.
Astrazeneca Plc
AZN
Sí, existe CEDEAR de AZN en Argentina. Operás bajo el ticker AZN en BYMA, con ratio 4:1 respecto a la acción en NYSE. Ratios y calculadora Ver próximos dividendos.
Empresa subyacente
HealthcareDrug Manufacturers - General
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies for rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, USA, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the multimodal foundation model in oncology; CSPC Pharmaceutical Group Limited to advance the discovery and development of oral candidates; Nucs AI Inc. to develop AI-driven Response Prediction for Therapeutic Radioconjugates; and Carterra, Inc. to advances lab-in-the-loop drug discovery through new scientific research collaboration. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is based in Cambridge, the United Kingdom.
- País
- United Kingdom
- Empleados
- 96.100
- Sitio web
- astrazeneca.com
Precio histórico
Últimos 230 días · 12/11/25 — 29/10/26
+11.61%
Cotización y datos
NYSERatio 4:1 · Subyacente AZN
CEDEAR (ARS)
Precio
$ 77.225
Var. %
+7,48%
Volumen operado
3.130
Subyacente (USD)
Precio AZN
US$ 186,65
Teórico (precio / ratio)
AZN ÷ 4
US$ 46,66
Dólar MEP (AZND)
Dividendos
Yield y fechas del subyacente vía Yahoo Finance. Ver calendario de dividendos.
Yield (USD)
1,8 %
Frecuencia (estimada)
Anual
Próxima ex-date
sin fecha
Próximo pago
sin fecha
Cobro estimado (anual)
Dividendo anual USD ÷ ratio 4
USD 0,80
Preguntas frecuentes
¿Existe CEDEAR de AZN en Argentina?
Sí, existe el CEDEAR de AZN (Astrazeneca Plc) en la Bolsa de Comercio de Buenos Aires (BYMA). Su ticker local es AZN.
¿Cuál es el ticker del CEDEAR de Astrazeneca Plc?
El ticker del CEDEAR de Astrazeneca Plc en Argentina es AZN. La acción subyacente cotiza en NYSE con el símbolo AZN.
¿Cuál es el ratio del CEDEAR AZN?
El CEDEAR AZN tiene un ratio de 4:1. Eso significa que 4 CEDEARs equivalen a 1 acción de AZN.
¿Cuánto vale el CEDEAR AZN hoy?
El CEDEAR AZN cotiza hoy a $ 77.225 en pesos argentinos, con una variación diaria de +7,48%.
¿Cuánto vale la acción AZN en dólares?
CEDEARs similares
Otros CEDEARs de Salud.
Noticias
Merck: A Strong Quarter, But It's Time To Take A Step Back
SeekingAlpha · 29 de oct de 2026
Merck's revenue rose in Q3 as Keytruda and Winrevair sales climbed, but overbought signals point to a pullback. Click for this MRK stock update.
